March 29, 2017
Port Erin Biopharma reports €0.5M profit for second half of 2016
Port Erin Biopharma Investments Limited has reported financial results for the six-month period ending 31 December 2016.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
March 28, 2017
The Parker Institute for Cancer Immunotherapy, BMS, CRI join to fight cancer
The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company and the Cancer Research Institute (CRI) have entered into a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks.
March 28, 2017
Milner Therapetucis Institute, Elysium Health partner up in developing preventive medicines
The Milner Therapeutics Institute is partnering up with Elysium Health to the Milner Therapeutics Consortium.
March 28, 2017
Xbrane Biopharma to deliver its cancer drug to Middle East
Xbrane Biopharma, a commercial phase Swedish biopharmaceutical company specialized in biosimilars and long acting injectables, has delivered its first batch of Spherotide to its partner in the Middle East to a value of €0.7 million.
March 28, 2017
Mylan underpayment on EpiPen could exceed proposed settlement -study
The amount that drugmaker Mylan NV avoided paying the U.S. government in Medicaid rebates for its EpiPen emergency allergy treatment since 2007 likely exceeds a proposed $465 million settlement the company announced in October, according to a study by private drug pricing experts published on Monday.
March 28, 2017
Sinclair Pharma halves loss in 2016
Sinclair Pharma has reported €18.8 million loss for 2016 which represents decrease comparing last years loss of €32.7 million.
March 28, 2017
Amryt kicks off third phase of skin disorder treatment AP101
Amryt has begun with “EASE”, the Phase 3 clinical trial of AP101, its lead drug candidate, which offers a potential treatment for a rare genetic skin disorder that causes fragile skin.
March 28, 2017
FDA OK’s Tesaro’s ovarian cancer drug
The U.S. Food and Drug Administration has approved Tesaro’s Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.
March 27, 2017
Alexion Pharmaceutical name new CEO
Alexion Pharmaceuticals’s Board of Directors has appointed Ludwig N. Hantson, Ph.D., as Chief Executive Officer and member of the Board of Directors, to succeed David R. Brennan, who has led the company as Interim CEO since December 2016.
March 27, 2017
Novo Nordisk’s new fast-acting mealtime insulin to sell in Canada
Novo Nordisk’s new, fast-acting mealtime insulin for the treatment of diabetes in adults, Fiasp has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017.